SG10201605529UA - Anti - amyloidogenic, alpha-helix breaking ultra-small peptide therapeutics - Google Patents

Anti - amyloidogenic, alpha-helix breaking ultra-small peptide therapeutics

Info

Publication number
SG10201605529UA
SG10201605529UA SG10201605529UA SG10201605529UA SG10201605529UA SG 10201605529U A SG10201605529U A SG 10201605529UA SG 10201605529U A SG10201605529U A SG 10201605529UA SG 10201605529U A SG10201605529U A SG 10201605529UA SG 10201605529U A SG10201605529U A SG 10201605529UA
Authority
SG
Singapore
Prior art keywords
amyloidogenic
alpha
small peptide
peptide therapeutics
helix breaking
Prior art date
Application number
SG10201605529UA
Inventor
Charlotte Hauser
Anupama Lakshmanan
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG10201605529UA priority Critical patent/SG10201605529UA/en
Publication of SG10201605529UA publication Critical patent/SG10201605529UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201605529UA 2011-07-07 2012-07-09 Anti - amyloidogenic, alpha-helix breaking ultra-small peptide therapeutics SG10201605529UA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG10201605529UA SG10201605529UA (en) 2011-07-07 2012-07-09 Anti - amyloidogenic, alpha-helix breaking ultra-small peptide therapeutics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG2011049780A SG187271A1 (en) 2011-07-07 2011-07-07 Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
SG10201605529UA SG10201605529UA (en) 2011-07-07 2012-07-09 Anti - amyloidogenic, alpha-helix breaking ultra-small peptide therapeutics

Publications (1)

Publication Number Publication Date
SG10201605529UA true SG10201605529UA (en) 2016-08-30

Family

ID=46514301

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011049780A SG187271A1 (en) 2011-07-07 2011-07-07 Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
SG10201605529UA SG10201605529UA (en) 2011-07-07 2012-07-09 Anti - amyloidogenic, alpha-helix breaking ultra-small peptide therapeutics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2011049780A SG187271A1 (en) 2011-07-07 2011-07-07 Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic

Country Status (6)

Country Link
US (1) US20140256625A1 (en)
EP (1) EP2729485B1 (en)
JP (1) JP2014524913A (en)
CN (1) CN103946232B (en)
SG (2) SG187271A1 (en)
WO (1) WO2013004399A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106414477A (en) * 2013-11-30 2017-02-15 新加坡科技研究局 Novel ultrashort hydrophobic peptides that self-assemble into nanofibrous hydrogels and their uses
AU2014355214A1 (en) * 2013-11-30 2016-07-07 Agency For Science, Technology And Research Self-assembling peptides, peptidomimetics and peptidic conjugates as building blocks for biofabrication and printing
CN103910782B (en) * 2014-03-18 2016-01-06 重庆大学 A kind of A beta peptide aggregation inhibitor
CN103992379B (en) * 2014-03-18 2016-06-15 重庆大学 A kind of A beta peptide aggregation inhibitor
EP3167277A4 (en) * 2014-07-08 2018-03-07 Agency For Science, Technology And Research Ultrashort peptides as exogenous second harmonic probes for bioimaging applications

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2871031B2 (en) * 1990-08-03 1999-03-17 日清製粉株式会社 Novel peptide and angiotensin converting enzyme inhibitors
US5639729A (en) * 1993-08-26 1997-06-17 Immunobiology Research Institute, Inc. Tripeptides useful in immune and CNS therapy
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
IL119466A (en) * 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
FR2788777B1 (en) * 1999-01-22 2003-01-17 Sederma Sa COSMETIC OR DERMOPHARMACEUTICAL USE OF PEPTIDES FOR THE REGULATION OF SKIN IMMUNOLOGICAL MALFUNCTIONS AND IN SKIN INFLAMMATION INDUCED BY AGING OR BY U.V.
KR20060133114A (en) * 1999-11-05 2006-12-22 액소닉스, 인코포레이티드. Peptide Analogs and Mimetics Suitable for in Vivo Use in the Treatment of Diseases Associated with Abnormal Protein Folding into Amyloid, Amyloid-like Deposits or β-Sheet Rich Pathological Precursor Thereof
AU2001289160A1 (en) * 2000-08-24 2002-03-04 Neuronz Ltd. Gpe analogs
JP3728494B2 (en) * 2000-09-04 2005-12-21 国立大学法人京都大学 Novel serum cholesterol-lowering peptide
CA2429359A1 (en) * 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
WO2006127702A2 (en) * 2005-05-23 2006-11-30 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
AU2003271745A1 (en) * 2002-07-08 2004-01-23 Laboratoires Serono Sa Beta-SHEET BREAKING PEPTIDES
WO2005007090A2 (en) * 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
US7632819B1 (en) * 2004-10-29 2009-12-15 Iowa State University Research Foundation, Inc. Methods and compositions for inhibiting PKC delta cleavage for treatment and prevention of neurodegeneration and apoptosis
WO2008003943A2 (en) * 2006-07-03 2008-01-10 Zapaloid Limited Inhibition of alpha-synuclein aggregation
DE102006052755A1 (en) * 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh New peptide derivatives and peptidomimetics are transglutaminase inhibitors useful for the treatment or prophylaxis of e.g. celiac disease, fibrosis, thrombosis, neurodegenerative disorders, Huntington's chorea and Parkinson disease
US8492341B2 (en) * 2006-11-28 2013-07-23 Alzyme Pty Ltd. Amyloid-β binding peptides
RU2488592C2 (en) * 2007-08-08 2013-07-27 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Peptides of directed action of vegfr-1/nrp-1
CA2698691A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2698768A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
EP2065029B1 (en) * 2007-11-30 2013-04-17 Evonik Goldschmidt GmbH Personal care and cosmetic composition containing tetrapeptides with the motifs GX1X2G, PX1X2P, or PX1X2K
CN102459313A (en) * 2009-05-08 2012-05-16 上海泰飞尔生化技术有限公司 High penetration prodrug compositions of peptides and peptide-related compounds

Also Published As

Publication number Publication date
EP2729485A1 (en) 2014-05-14
CN103946232A (en) 2014-07-23
SG187271A1 (en) 2013-02-28
EP2729485B1 (en) 2017-06-07
JP2014524913A (en) 2014-09-25
WO2013004399A1 (en) 2013-01-10
CN103946232B (en) 2017-07-21
US20140256625A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
GB2496711B (en) Keyswitch
SI3833023T1 (en) Merge candidate list construction
IL231761A0 (en) Recombinant self-replicating polycistronic rna molecules
FI20110196A0 (en) Switch
EP2797634A4 (en) Modified mrnas encoding cell-penetrating polypeptides
EP2709134A4 (en) Two-stage switch
DK2797616T3 (en) CELL-PENETRATING PEPTIDES
ZA201401140B (en) Polypeptide separation methods
EP2754069A4 (en) Hyperlink destination visibility
ZA201307169B (en) Neuroprotective peptides
SG10201605529UA (en) Anti - amyloidogenic, alpha-helix breaking ultra-small peptide therapeutics
EP2865686A4 (en) Egfr-binding peptide
DE112012005172A5 (en) switch
GB201220899D0 (en) CD44v6-derived pegylated peptides
HK1187628A1 (en) Novel peptide
EP2891663B8 (en) Psf1-derived peptide
GB2488127B (en) Operation system for umbrellas
FR2986528B1 (en) NEW ANTI-AGING PEPTIDES
DE112012001788A5 (en) switch arrangement
HK1152455A2 (en) Combined type impact point flasher
PT2718316T (en) Polypeptides
GB201112985D0 (en) Polypeptide
IT1403345B1 (en) SWITCH
GB201200743D0 (en) Protein bridges
IT1407209B1 (en) ANTIVIRAL PEPTIDES.